Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis DOI Creative Commons
Sibel Ali, Ana Ion, Olguţa Anca Orzan

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(11), P. 1425 - 1425

Published: Nov. 7, 2024

Atopic dermatitis is one of the most common inflammatory skin diseases, with an increasing incidence among both children and adults. The recurrent nature, often persistence symptoms, polymorphism response to current therapies have led increased research in therapeutic area dedicated this condition. understanding pathophysiological pathways has contributed development innovative therapies, including biological JAK inhibitors, but also emerging technologies like nanotechnology-based drug delivery systems. These innovations promise enhanced efficacy, reduced side effects, improved patient outcomes. ongoing exploration novel vehicles, formulations, natural biopolymers, along cutting-edge agents tapinarof mesenchymal stem cells, highlights potential for even more precise personalized management AD future. Despite these advances, challenges persist, particularly ensuring long-term safety, accessibility, broader application necessitating continued development.

Language: Английский

Topical anti-inflammatory treatments for eczema: network meta-analysis DOI
S. Lax, Eleanor Van Vogt, Bridget Candy

et al.

Cochrane library, Journal Year: 2024, Volume and Issue: 2024(8)

Published: Aug. 6, 2024

Language: Английский

Citations

9
Oleoylethanolamide ameliorates allergic asthma and atopic dermatitis via activation of GPR119 DOI

Jung-Eun Lee,

Dong‐Soon Im

International Immunopharmacology, Journal Year: 2025, Volume and Issue: 149, P. 114258 - 114258

Published: Feb. 10, 2025

Language: Английский

Citations

1
Topical Anti‐Inflammatory Treatments for Eczema: A Cochrane Systematic Review and Network Meta‐Analysis DOI Creative Commons
S. Lax, Eleanor Van Vogt, Bridget Candy

et al.

Clinical & Experimental Allergy, Journal Year: 2024, Volume and Issue: 54(12), P. 960 - 972

Published: Sept. 2, 2024

Eczema is the most burdensome skin condition worldwide and topical anti-inflammatory treatments are commonly used to control symptoms. The relative effectiveness safety of different uncertain.

Language: Английский

Citations

4
The Role of Aryl Hydrocarbon Receptor in Skin Homeostasis: Implications for Therapeutic Strategies in Skin Disorders DOI Open Access

Jundan Yang,

Pei Qiao, Gang Wang

et al.

Cell Biochemistry and Function, Journal Year: 2025, Volume and Issue: 43(2)

Published: Jan. 27, 2025

ABSTRACT The aryl hydrocarbon receptor (AhR), a ligand‐activated transcription factor, is extensively expressed in diverse human organs and plays pivotal role mediating the onset, progression, severity of numerous diseases. Recent research has explored substantial impact AhR on skin homeostasis related pathologies. As multi‐layered organ, comprises multiple cell populations that express AhR. In this review, we introduce various cells its barrier function. Furthermore, explore involvement development diseases, highlighting potential as therapeutic target for disorders. By targeting AhR, may open new avenues novel efficient disease treatments.

Language: Английский

Citations

0
Efficacy and Safety of Proactive Therapy with 2% Crisaborole Ointment in Children with Mild-to-Moderate Atopic Dermatitis: A Randomized Controlled Study DOI
Huan Yang, Ping Li, Hong Shu

et al.

Pediatric Drugs, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 28, 2025

Language: Английский

Citations

0
Changes and clinical significance of serum vitamin A, 25-(OH)D3, TG2, IL-4 and IL-13 levels in children with eczema DOI
Yulian Li, Zhanhui Wang, Xuehua Li

et al.

Archives of Dermatological Research, Journal Year: 2025, Volume and Issue: 317(1)

Published: Feb. 8, 2025

Language: Английский

Citations

0
Dermatological diseases predisposing to the development of otitis externa (literature review) DOI
А. С. Дворников, T. A. Gaydina, Kriukov Ai

et al.

Russian Bulletin of Otorhinolaryngology, Journal Year: 2025, Volume and Issue: 90(1), P. 50 - 50

Published: March 18, 2025

Otitis externa is the most common diagnosis in practice of an otorhinolaryngologist. Definitions term are not precise at moment, and a universal generally accepted classification has been developed. In separate nosological group, otitis can be distinguished from background dermatological diseases. These patients need interdisciplinary approach, joint supervision otorhinolaryngologists dermatovenerologists to increase effectiveness treatment minimize risks chronic otitis. Severe complications obstructive keratosis, fibrous atresia, persistent conductive hearing loss. Diagnostic algorithms therapeutic strategies for should include search therapy disease. At tactics managing suffering on diseases continues

Language: Английский

Citations

0
Safety and Efficacy of Non‐Steroidal Topical Aryl Hydrocarbon Receptor Agonists for the Treatment of Atopic Dermatitis: A Systematic Review and Meta‐Analysis of Randomised Controlled Trials DOI
Martin Cevallos‐Cueva,

Carlos Alberto Monteiro Leitão Neto,

Devanie Martani

et al.

Australasian Journal of Dermatology, Journal Year: 2025, Volume and Issue: unknown

Published: April 7, 2025

ABSTRACT Background Current first‐line topical treatments for atopic dermatitis (AD) are often limited by concerns related to age, systemic absorption, especially when applied large body surface areas or under maximal usage conditions and undesirable adverse events (AEs), highlighting the need alternative therapies. Methods We performed a systematic review meta‐analysis of seven randomised controlled trials (RCT) comparing aryl hydrocarbon receptor agonists (TAHRA), including tapinarof benvitimod cream, vehicle at different concentrations application frequencies in patients with AD, which evaluated outcomes such as Investigator Global Assessment (IGA) scores/Validated Investigator's (vIGA), Eczema Area Severity Index (EASI‐75), change from baseline area (BSA) pruritus score (PS) safety profiles. Results A total 1631 patients, 1086 received TAHRA, while 545 vehicle. Overall, TAHRA led significant improvement IGA/vIGA scores (RR 2.38; 95% CI 1.68 3.37; p < 0.0001), EASI‐75 2.94; 2.07 4.17; 0.00001). Similar findings were observed mean BSA% (MD −6.08; −8.00 −4.16; 0.00001), PS (Std MD −0.90; −1.41 −0.39; = 0.0006). The incidence AE was significantly higher group 1.48; CI: 1.19–1.85; 0.0005). found no difference serious (SAEs) 1.51; 0.34–6.64; 0.59). Treatment‐emergent (TEAEs), folliculitis, more frequent 8.06; 2.75–23.60; 0.0001). Conclusion Our support efficacy among metrics minimal tolerable AEs its use valuable new non‐steroidal option treatment AD.

Language: Английский

Citations

0
Emerging Treatments and New Vehicle Formulations for Atopic Dermatitis DOI Creative Commons
Sibel Ali, Ana Ion, Olguţa Anca Orzan

et al.

Pharmaceutics, Journal Year: 2024, Volume and Issue: 16(11), P. 1425 - 1425

Published: Nov. 7, 2024

Atopic dermatitis is one of the most common inflammatory skin diseases, with an increasing incidence among both children and adults. The recurrent nature, often persistence symptoms, polymorphism response to current therapies have led increased research in therapeutic area dedicated this condition. understanding pathophysiological pathways has contributed development innovative therapies, including biological JAK inhibitors, but also emerging technologies like nanotechnology-based drug delivery systems. These innovations promise enhanced efficacy, reduced side effects, improved patient outcomes. ongoing exploration novel vehicles, formulations, natural biopolymers, along cutting-edge agents tapinarof mesenchymal stem cells, highlights potential for even more precise personalized management AD future. Despite these advances, challenges persist, particularly ensuring long-term safety, accessibility, broader application necessitating continued development.

Language: Английский

Citations

0